InvestorsHub Logo
Followers 0
Posts 3
Boards Moderated 0
Alias Born 05/23/2017

Re: None

Sunday, 06/25/2017 6:17:13 AM

Sunday, June 25, 2017 6:17:13 AM

Post# of 2104
Very curious why there was no PR for the Orphan designation? This does not appear to be Emricasan (else it would be listed under that name, as there is another entry currently), it seems this is one of their retained compounds IDN-7314 which they mention in their Needham presentation treats Primary Sclerosing Cholangitis.

This seems like huge news to me...one of CNAT's biggest flaws was being a "one trick pony", but this seems proof they are moving ahead with additional drugs.